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Best Practices for Health Care Professionals on the Use of 
Polymerase Chain Reaction (PCR) for Diagnosing Pertussis
Summary
With the continuing resurgence o f pertussis, health care professionals will likely see more 
patients with suspected pertussis. Proper testing criteria, timing o f testing, specimen collection 
techniques, protocols for avoiding specimen contamination, and appropriate interpretation of  
test results are all necessary to ensure that Polymerase Chain Reaction (PCR) reliably informs 
patient diagnosis. PCR is an important tool for timely diagnosis ofpertussis and is increasingly 
available to clinicians. PCR is a molecular technique used to detect DNA sequences o f the 
Bordetella pertussis bacterium and unlike culture does not require viable (live) bacteria present 
in the specimen. Despite this advantage, PCR can give results that are falsely-negative or 
falsely-positive. The following compilation o f best practices is intended to help health care 
professionals optimize the use o f PCR testing for pertussis by avoiding some o f the more 
common pitfalls leading to inaccurate results.
Recommendations for Testing 
Whom should you test?
Only patients with signs and symptoms consistent with pertussis should be tested by PCR
to confirm the diagnosis. When bacterial DNA is still present in the nasopharynx, because after 
the fourth week of cough, the amount of bacterial DNA rapidly diminishes, increasing the risk of 
obtaining falsely-negative results by PCR. For more information on diagnostic testing, see 
http://www.cdc.gov/pertussis/clinical/features.html. Testing asymptomatic persons should be 
avoided as it increases the likelihood of obtaining falsely-positive results. Asymptomatic close 
contacts of confirmed cases should not be tested and testing of contacts should not be used for 
post-exposure prophylaxis decisions.
When should you test?
When possible, you should test patients for pertussis during the first 3 weeks of cough. For
guidance in distinguishing signs and symptoms of pertussis from those of other conditions, see 
http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-confirmation.html. Also, PCR 
testing after 5 days of antibiotic use is unlikely to be of benefit, because PCR testing following 
antibiotic therapy also can result in falsely-negative findings, although the exact duration of 
positivity following antibiotic use is not well understood.
How should you obtain specimens?
You should obtain specimens for PCR by aspiration or swabbing the posterior
nasopharynx, rather than by throat swabs or anterior nasal swabs which both have unacceptably 
low rates of DNA recovery and should therefore not be used for pertussis diagnosis. For more 
information, see http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis- 
confirmation.html.
What should you do to avoid contamination o f  clinical specimens with 
pertussis DNA?
Some pertussis vaccines [1] have been found to contain PCR-detectable B. pertussis DNA. 
Environmental sampling has identified B. pertussis DNA from these vaccines in clinic 
environments. While DNA in the vaccines does not impact the safety or immunogenicity, 
accidental transfer of the DNA from environmental surfaces to a clinical specimen can 
result in specimen contamination and falsely-positive results. If health care professionals 
adhere to good practices, there is no need to switch vaccines. Clinicians should adhere to the 
following vaccine preparation and administration best practices and basic infection-control 
measures, to prevent cross-contamination.
Best Practices fo r  Preparing and Administering Vaccines
• Prepare and administer vaccines in areas separate from pertussis specimen collection because 
doing so may reduce the opportunity for cross contamination of clinical specimens.
• Take care to avoid contamination of surfaces when preparing and administering vaccines.
Adherence to Basic Infection-control Measures
• Wearing clean gloves immediately before and during specimen collection or vaccine 
preparation and administration with immediate disposal of gloves after the procedure, and
• Cleaning clinic surfaces using a 10% bleach solution to reduce the amount of nucleic acids in 
the clinic environment.
The use of liquid transport media likely also contributes to falsely-positive results from 
contaminant DNA. When using liquid transport media, DNA that is accidentally transferred from 
hands to the swab shaft can be washed off into the liquid medium which freely circulates around 
the transport tube; this liquid is later extracted to obtain DNA for PCR testing. Use of a semisolid 
or non-liquid transport media or transport of a dry swab without media should prevent 
contaminant DNA on the swab shaft from reaching the part of the specimen that is later 
extracted. If using liquid transport medium, the swab stick should be handled with care and only 
above the red line or indentation which marks where the shaft is snapped off after insertion into 
the medium. Performing NP aspiration rather than swabbing the NP may also prevent 
contamination from occurring as the aspirate kit (syringe or bulb style) is a closed system at the 
point of specimen collection.
Recommendations, Understanding and Interpreting PCR Results
PCR assays for pertussis are not standardized across clinical laboratories. Testing methods, DNA 
targets used, and result interpretation criteria vary, and laboratories do not use the same cutoffs 
for determining a positive result. With PCR, high cycle threshold (Ct) values indicate low levels 
of amplified DNA; for pertussis, these values may still indicate infection but can also be the 
result of specimens contaminated with DNA from the environment at the time of specimen 
collection. Clinical laboratories might report high Ct values as any of the following: positive, 
detected, indeterminate, or equivocal. In addition, most clinical laboratories use a single target 
PCR for IS481, which is present in multiple copies in B.pertussis and in lesser quantities in B. 
holmesii and B. bronchiseptica. Because this DNA sequence is present in multiple copies, IS481 
is especially susceptible to falsely-positive results. Use of multiple targets may improve 
specificity of PCR assays for pertussis. Clinicians are encouraged to inquire about which 
PCR target or targets are used by their laboratories. Interpretation of PCR results, 
especially those with high Ct values, should be done in conjunction with an evaluation of 
signs and symptoms and available epidemiological information.
For More Information:
• For the entire guidance on PCR best practices in diagnosing pertussis, see 
http://www.cdc.gov/pertussis/clinical/diagnostic-testing/diagnosis-pcr-bestpractices.html
• For distinguishing clinical features of pertussis, see 
http://www.cdc.gov/pertussis/clinical/features.html
• For more information on diagnostic testing, see 
http://www.cdc.gov/pertussis/clinical/diagnostic-testing/index.html
• CDC toll-free information line, 800-CDC-INFO (800-232-4636)TTY: (888) 232-6348, is 
available 24 hours a day, every day.
Footnote
1. Vaccines shown to contain PCR-detectable DNA include Pentacel®, Daptacel®, and 
Adacel®. Leber A et al. Detection of Bordetellapertussis DNA in Acellular Vaccines and in 
Environmental Samples from Pediatric Physician Offices, in 2010 Interscience Conference on 
Antimicrobial Agents and Chemotherapy (ICAAC): Boston, USA.
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preventing and controlling diseases and injuries; enhances health decisions by providing 
credible information on critical health issues; and promotes healthy living through strong 
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